Quick Facts

• Primary Use: Management of abdominal pain and cramping.
• Therapeutic Domain: Conditions involving spasms in the gastrointestinal, urinary, and biliary tracts.
• Effect: Helps provide symptomatic relief from painful smooth muscle contractions.

---

Butylscopolamine is a medication utilized for the symptomatic management of discomfort and pain related to smooth muscle spasms. Its main applications involve conditions that cause painful contractions in the body's systems.

Specifically, this agent is indicated for the treatment of abdominal cramping and pain. This includes discomfort associated with general gastrointestinal spasms, as well as those related to conditions like irritable bowel syndrome (IBS). It may help provide relief from the visceral pain and cramping sensations associated with these disorders. The medication is also utilized to address spasms in the urinary and biliary tracts, which may be associated with conditions like renal or biliary colic.

Furthermore, butylscopolamine may be used as part of certain diagnostic and therapeutic procedures, such as endoscopy, to reduce motility in the gastrointestinal tract and facilitate the procedure.

Official Eligibility and Contraindications

Regulatory agencies define strict rules for who can and cannot use Butylscopolamine (Hyoscine butylbromide), primarily due to its anticholinergic properties and the potential to worsen specific medical conditions.

Classification	Eligibility Status (Regulatory Basis)
Populations Allowed	Adults and adolescents over 12 years. Children are generally allowed from 6 years of age for oral tablets, although use is not recommended below this threshold.
Contraindicated Groups	Patients with myasthenia gravis, megacolon, paralytic or obstructive ileus, or mechanical stenosis in the gastrointestinal tract.

---

Absolute Exclusions (Contraindications)

The medicine must not be used by individuals with untreated narrow-angle glaucoma or known hypersensitivity to the drug. The injectable form carries additional prohibitions, being contraindicated in patients with conditions like tachycardia or cardiac failure.

Restricted and Conditional Use

Special caution is required for patients prone to urinary outlet obstructions (e.g., prostatic enlargement) or intestinal obstructions. Regarding reproductive status, use is not recommended during pregnancy or breastfeeding due to limited or insufficient human data.

Interactions with other medicines and products

The interaction profile of Butylscopolamine is primarily defined by the potential for additive or antagonistic pharmacological effects when co-administered with specific medicinal products.

Documented Interactions

Interaction Type	Interacting Product Categories	Practical Implication
Additive Anticholinergic Effects	Other anticholinergics, Tricyclic/Tetracyclic Antidepressants, Antihistamines, Quinidine, Amantadine, Disopyramide	Enhanced peripheral anticholinergic effects may occur.
Additive Cardiovascular Effects	Beta-agonists (e.g., Tiotropium, Salbutamol)	Increased risk or severity of tachycardia.
Antagonistic Effects	Dopamine Antagonists (e.g., Metoclopramide, Domperidone)	Reduced efficacy of both agents due to counteracting effects on gastrointestinal motility.
Absorption Interference	Antacids, Adsorbent Anti-diarrhea Products	Reduced absorption of Butylscopolamine, necessitating a required temporal separation of administration (at least 1 hour).
Procedural Restriction	Anticoagulant Drugs	Intramuscular administration should be avoided due to the increased risk of haematoma; alternative routes must be used.

Co-administration with other substances that cause sedation, such as opioid pain relievers or sedatives, may result in enhanced sedative effects. The combination of Butylscopolamine with other medicines requires clinical evaluation to manage the increased risks associated with these documented interactions.

Blocking the Cholinergic Command

Hyoscine butylbromide acts as a competitive antagonist primarily at peripheral muscarinic acetylcholine receptors ( M-AChRs) located on nerve endings and smooth muscle cells. This interaction prevents the stimulatory neurotransmitter, acetylcholine ( ACh), from binding, effectively interrupting the neural command that drives muscle activity and tone.

---

⬇️ Interrupting the Contraction Cascade

The M-AChR blockade modifies the subsequent cellular cascade, specifically preventing the crucial release of intracellular calcium ions ( Ca^2+) required for muscle contraction. This molecular action directly leads to the core physiological consequence of smooth muscle relaxation (spasmolysis) in the visceral hollow organs, reducing their tone and motility.

---

️ Mechanism Confined to the Periphery

The drug's chemical structure as a quaternary ammonium compound makes it highly polarized, restricting its ability to cross the blood-brain barrier (BBB). This ensures that the mechanism's physiological effects—the reduction of visceral signaling—are exclusively peripheral and do not modulate central nervous system (CNS) function.

Butylscopolamine (hyoscine butylbromide) is available in two distinct official forms: 10 mg oral tablets and a 20 mg/mL sterile solution for injection. The approved administration methods encompass the oral route as well as parenteral administration via intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection.

Standard oral dosing for adults and adolescents (12 years and older) involves a dose of 10 mg to 20 mg, administered up to four times daily. The parenteral solution is used for acute situations with a single dose of 20 mg, which may be repeated after half an hour if clinically indicated, with a maximum total daily dose of 100 mg. A procedural condition of use is that IV injection should be administered slowly.

Specific usage instructions require that oral tablets must be swallowed whole with water and must not be crushed, broken, or chewed. For pediatric patients aged 6 to 11 years, the official oral dose is 10 mg, three times daily. However, official recommendations for parenteral use in children under 12 years vary by region; some labels advise against use, while others provide body-weight-based dosing for severe cases. Critically, official labeling states the medicine should not be taken on a continuous daily basis or for extended periods without a medical investigation into the cause of the underlying symptoms. This duration constraint defines the usage pattern as short-term and intermittent.

Research Evidence Overview

Butylscopolamine (also known as hyoscine butylbromide) is a spasmolytic compound classified by the World Health Organization (WHO) as an essential medicine. Its primary indication is for the relief of spasms of the gastrointestinal tract.

Efficacy Studies

Clinical trials have primarily focused on the compound’s relationship with pain and discomfort caused by smooth muscle contractions, such as abdominal cramps. A review of studies, including some randomized controlled trials (RCTs), explored the measurements of pain relief, particularly when butylscopolamine was used for functional abdominal complaints. The results suggest the measurements of symptom improvement are comparable to other over-the-counter options, such as acetaminophen or peppermint oil, in real-world settings.

In specialized areas, such as the management of renal colic, research has been mixed. Recent, rigorous RCTs investigated whether continuous intravenous butylscopolamine was non-inferior to placebo for pain relief, with some data suggesting no benefit in reducing the need for additional pain medication in this specific, severe pain setting.

Safety and Tolerability Profile

The compound is a quaternary amine, which limits its ability to cross the blood-brain barrier. This structural feature is associated with a lower likelihood of central nervous system (CNS) side effects compared to muscarinic antagonists with a tertiary amine structure.

Across clinical development programs, adverse events reported most frequently were:

• Dry mouth
• Constipation
• Blurred vision
• Tachycardia (increased heart rate)

The overall rate of serious adverse events (SAEs) in trials was generally monitored and reported to be similar between butylscopolamine and placebo groups. Study protocols have specifically excluded participants with conditions like narrow-angle glaucoma or certain types of heart disease to ensure the compound's tolerability within the defined research scope.

Common questions about Butylscopolamine (FAQ)

---

Q: How quickly will Butylscopolamine start working for my back pain?

Clinical studies suggest that some individuals may begin to experience pain relief within the first week of starting treatment. However, achieving the full pain-relieving potential of the medication may take longer, with maximum benefit often observed after 2 to 4 weeks of consistent use. Consistent use, as prescribed by a healthcare provider, is generally necessary to achieve the maximum potential benefit. If relief has not been experienced after one month, it is important to consult a healthcare provider for further guidance.

---

Q: Can I take Butylscopolamine with my other pain medications, like ibuprofen?

There may be an increased risk of gastrointestinal side effects, such as stomach bleeding and ulcers, when Butylscopolamine is combined with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. This potential interaction should be discussed with a healthcare professional before starting treatment. A healthcare provider is the best resource to determine if this combination is appropriate for an individual's specific health profile. It is essential to inform a healthcare provider about all medications being taken so they can assess potential interactions and provide guidance.

---

Q: What happens if I accidentally miss a dose of Butylscopolamine?

If a dose is missed, regulatory instructions typically advise taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the product label directs the individual to skip the missed dose and continue with the regular schedule. Taking two doses at once is generally advised against due to the potential for increased side effects. If multiple doses are missed, consulting a pharmacist or healthcare provider is recommended for personalized advice on restarting the medication.

---

Q: Is Butylscopolamine safe to take if I have high blood pressure or heart problems?

Butylscopolamine may potentially cause fluid retention and increases in blood pressure, which could require careful management in individuals with pre-existing heart or blood pressure conditions. The decision to prescribe Butylscopolamine in these cases involves a careful assessment of risks and benefits by a healthcare provider. When prescribed, a healthcare provider will determine if the benefits outweigh the risks and may recommend regular monitoring. Any necessary dietary adjustments, such as a low-sodium diet, should be discussed directly with a healthcare provider.

Storage Conditions

Official storage requirements for Butylscopolamine (Hyoscine Butylbromide) vary by formulation. Injectable solutions must be stored at temperatures not exceeding 30^circC and protected from light. Tablet formulations may not require any special temperature storage conditions, but must be kept in the original container to protect from moisture.

After opening or dilution, the injection solution is for immediate use only, and any unused portion must be discarded. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements for medicinal waste. The medicine must not be disposed of by throwing it into household waste or wastewater.